A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)
Completed · Phase 1/Phase 2
Conditions studied: Blood Cancer, Myelodysplastic Syndromes, Myelodysplastic Syndromes (MDS)
In brief
The primary objectives of the trial are to assess erythroid response to darbepoetin alfa, as determined by changes in hemoglobin and/or red blood cell (RBC) transfusion-dependence and to describe the safety profile of darbepoetin alfa in patients with MDS. The secondary objective is to assess bone marrow progenitor BFU-E growth before and after treatment with darbepoetin alfa.
Key facts
- Study ID
- NCT00230321
- Run by
- Peter L Greenberg
- People needed
- 21
- Starts
- 2002-02-01
- Expected to finish
- 2008-01-01
- Last updated by the study team
- 2013-02-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford University School of Medicine — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.